Innovate Biopharmaceuticals Initiates P-III Clinical Study for Celiac Disease

 Innovate Biopharmaceuticals Initiates P-III Clinical Study for Celiac Disease

IInnovate Initiates its Dosing For P-III CeD LA 3001 Trial for Celiac Disease

Shots:

  • Innovate Biopharmaceuticals announces the initiation of P-III clinical study of INI-202 for Celiac disease with its expected screening & enrollment updates in next few months
  • The P-III clinical study is the one of key event for addressing needs of Celiac patients with continued symptoms despite being on a gluten-free diet
  • Innovate focuses on developing therapies for autoimmune and inflammatory diseases including its lead candidate larazotide acetate, renormalizing dysfunctional intestinal barrier by reducing intestinal permeability & antigen trafficking

Click here to read full press release/ article | Ref: Innovate Biopharmaceuticals | Image: University of Virginia

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post